Muscle Invasive Bladder Cancer Clinical Trials

4 recruiting

Muscle Invasive Bladder Cancer Trials at a Glance

19 actively recruiting trials for muscle invasive bladder cancer are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Austin, Los Angeles, and Cincinnati. Lead sponsors running muscle invasive bladder cancer studies include Ferring Pharmaceuticals, The First Affiliated Hospital with Nanjing Medical University, and First Affiliated Hospital of Chongqing Medical University.

Browse muscle invasive bladder cancer trials by phase

Treatments under study

About Muscle Invasive Bladder Cancer Clinical Trials

Looking for clinical trials for Muscle Invasive Bladder Cancer? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Muscle Invasive Bladder Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Muscle Invasive Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 119 of 19 trials

Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled82 locationsNCT06510374
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled14 locationsNCT07283835
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled66 locationsNCT06545955
Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

Breast CancerLiver CancerPancreatic Cancer+9 more
Natera, Inc.9,600 enrolled1 locationNCT07318051
Recruiting
Phase 2

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Not Applicable

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Bladder CancerMuscle Invasive Bladder Cancer (MIBC)Muscle Invasive Bladder Cancer Urothelial Carcinoma+1 more
Johns Hopkins University130 enrolled2 locationsNCT07225205
Recruiting
Phase 2

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Theralase® Technologies Inc.90 enrolled16 locationsNCT03945162
Recruiting
Phase 1Phase 2

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)Clear Cell Renal Cell Cancer (ccRCC)+4 more
ITM Oncologics GmbH270 enrolled10 locationsNCT05706129
Recruiting
Phase 1Phase 2

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
ImmunityBio, Inc.596 enrolled80 locationsNCT02138734
Recruiting
Not Applicable

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Muscle Invasive Bladder Cancer
Assiut University76 enrolled2 locationsNCT07202819
Recruiting
Phase 3

Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer

Bladder CarcinomaBladder NeoplasmMuscle Invasive Bladder Cancer (MIBC)+2 more
University of Rome Tor Vergata92 enrolled1 locationNCT07067749
Recruiting
Not Applicable

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT07036731
Recruiting
Phase 2

Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC

Non Muscle Invasive Bladder Cancer
Relmada Therapeutics, Inc.70 enrolled1 locationNCT06663137
Recruiting
Phase 1

Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

Muscle Invasive Bladder Cancer
First Affiliated Hospital of Chongqing Medical University10 enrolled1 locationNCT06916494
Recruiting
Phase 1

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.170 enrolled1 locationNCT06108492
Recruiting
Phase 1Phase 2

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

High-risk Non-muscle Invasive Bladder Cancer
RemeGen Co., Ltd.24 enrolled6 locationsNCT06378242
Recruiting
Not Applicable

The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection

Non Muscle Invasive Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University428 enrolled1 locationNCT06287541
Recruiting

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Bladder CancerBladder NeoplasmNon Muscle Invasive Bladder Cancer+8 more
IRCCS San Raffaele20,000 enrolled1 locationNCT06167356